EXPERIMENTAL ANIMAL FACILITY
The Animal Facility of NICED consists of two units. The old
facility is present at the premises of S.C.PAL-Building. This
has undergone phase wise modernization and at present it looks
like a new version of old Animal House. The new facility is
developed at the JICA-building premises of NICED with modern
technological outfits. As a whole, the entire facility is
updated to cater the need of Scientific Research of this
The following species are bred here up till now in order to
meet up the desired supply target under controlled programmes
amongst our own researchers complying with the scheduled ethical
- Albino Mice (Swiss strain)- Random Breeding.
- -----Do------ (Balb-C strain)- In Breeding.
- Black Mice (C57BL/6 strain)- In Breeding.
- Albino Rats (Ducrey strain)- Random Breeding.
- Golden Hamsters - Out Breeding.
- Albino Rabbits (New-Zealand White)- Out Breeding.
Animal experiments are being done observing all Animal Ethics
Regulations streamlined by the ‘Institutional Animal Ethics
Committee’ (IAEC) concerned under the guidance of the ‘Committee
for the Purpose of Control and Supervision of Experiments on
Animals’ (CPCSEA), Govt. of India.
Biomedical Informatics Centre (BIC) at the National Institute of
Cholera and Enteric Diseases, Kolkata was established in
September, 2006. This is the one of the seven centers created by
Indian Council of Medical Research (ICMR), Govt. of India.
Biosafety Level-3 Laboratory (BSL3)
BSL-3 is suitable for work with infectious agents which may
cause serious or potentially lethal diseases as a result of
exposure even through aerosol. In wake of increasing threat of
highly pathogenic viral infections such as Avaian Influenza,
Ministry of Health and Family Welfare provided funds in 2006 for
setting up a BSL3 laboratory at NICED to cater to the Eastern
states of India. BSL3 laboratory was installed and inaugurated
at NICED in 2007 in the ID and BG hospital Campus by Director
General, ICMR in the presence of Additional Chief Secretary,
Govt of West Bengal and other dignitaries from the State Health
Department. During the Avian Influenza outbreak in poultry in
West Bengal during January-February 2008, all suspected human
samples were handled and analyzed by Real time PCR at BSL3
laboratory . Results were provided to the WB State Health Dept.
and ICMR HQ within 24h after receiving samples. This facility is
under the Division of Virology.
NICED along with International Vaccine
institute, Seoul, Korea initiated a project titled “Surveillance
for typhoid fever and cholera in eastern Kolkata, West Bengal,
India” in 2001 to generate accurate epidemiologic,
socio-behavioral, and economics data on typhoid fever and
cholera in impoverished slum area populations of eastern Kolkata
in preparation for field trials of vaccines against these two
diseases. It is basically a health care facility-based passive
surveillance; nested case-control studies done among urban slum
population (60,000) of Kolkata in ward 29 and 30.
It was followed by the typhoid (Vi) vaccination project titled
“Randomized controlled evaluation of protection by the Vi
polysaccharide vaccine against typhoid fever in eastern Kolkata,
West Bengal, India” among 60, 000 urban slum population in 2004
with a coverage of 69%. The study population was followed up for
2 years to estimate the effectiveness of the vaccine. The study
ended in 2006. The result was very promising, preliminary
analysis shows an over all protective efficacy of 61%.
After the typhoid vaccine trial, NICED -IVI undertook a phase II
trial to see the safety and immunogenicty of the bivalent, whole
cell killed oral cholera vaccine in Kolkata among healthy
volunteers aged 1 year and above up to 40 years. It was proven
to safe and immunogenic.
After the typhoid vaccine trial, NICED -IVI undertook a trial on
bivalent, whole cell killed oral cholera vaccine titled “A
Randomized Controlled Trial of The Bivalent Killed Whole Cell
Oral Cholera Vaccine in Eastern Kolkata, West Bengal, India”
among 110,000 urban slum populations in ward 29, 30 and 33 of
Kolkata Municipal Corporation. The primary objective of the
study is to see the protective efficacy of the vaccine against
Vibrio Cholerae O1 and O139 among subjects 1 year and above. It
was a double dose vaccine with2 weeks gap in between the doses.
The coverage was 61% for the two doses. The vaccination ended on
10th September 2006. The study subjects will be followed up for
Along with these trials NICED also under took Socio-behavioral
and economic studies on typhoid fever and cholera to estimate
the economic costs of cholera and typhoid fever in the community
In 2007, NICED-IVI did a trial on the same oral cholera vaccine
to compare the immune response of the vaccine after 1st dose and
second dose. Preliminary results show significant rise in
vibriocidal titre after 1st dose of the vaccine which may pave
the way for introducing this vaccine in public health program of
India especially in endemic areas to combat cholera epidemics.
NICED has already done a large community based trial to see the
efficacy of probiotic in preventing diarrhoeal diseases among
the children, in collaboration with Yakult Honsa, Japan. A multi
centric diarrhoeal diseases burden study is already on, with
collaboration with University of Maryland. It’s a large
community based case control study. The study populations are
urban slum dwellers in Kolkata.
Another phase II trial is coming up with the same vaccine among
the infants as well.
In the coming years NICED is planning to undertake several
vaccine trials collaborating with IVI. on live oral typhoid
vaccine among children aged 2-17 years to see the safety,
immunogenicity which will be followed by large scale community
based phase III trial,
NICED is also planning for phase II safety trial of a live oral
cholera vaccine in collaboration with Department of
Biotechnology and another phase II trial of Peru 15 (live oral
cholera vaccine) with International Vaccine Institute. Apart
from these, we are preparing a protocol for a mass vaccination
project with the oral killed cholera vaccine in endemic areas
keeping another set of population as reference population with
international Vaccine Institute and a single dose efficacy study
of the whole cell killed oral cholera vaccine.
The Institute has a central
instrumentation facility located in the 3rd floor of S. C. Pal
Building. Due to recent expansion, another set up will be coming
up soon in the 2nd floor of JICA building. The central facility
is equipped with high-speed centrifuges, ultracentrifuges,
spectrophotometer, sonicator, and shakers for large bacterial
cultures. This facility is being upgraded time to time.
Recently, a large number of sophisticated instruments have been
procured and these are placed under scientists for proper
maintenance and utilization. These include FPLC, HPLC, LC-MS,
calorimeters like ITC and DSC, FACS, confocal microscope,
electron microscope, real-time PCR and automated DNA sequencer.
The instruments are available for use mainly by our scientists
and our collaborators.
Hematology, Clinical Biochemistry ..
More on Clinical Laboratory